{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "9db588195176fdb47be7ef0a32ebcb76",
    "title": "Jefferies",
    "source_uri": "25.9月 普通个人版/9.1 普通个人版/Jefferies/FY25 - Dont Back DownFY25 - Dont Back Down_2025-08-28",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-26T12:19:13.475490",
      "extracted_at": "2025-10-26T12:19:13.475504"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 15,
        "successful_pages": 15,
        "date": "2025-08-28",
        "publication": "25.9月 普通个人版/9.1 普通个人版/Jefferies",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 2,
          "removed_paragraphs": 8,
          "reduction_ratio": 0.15372125619284194
        },
        "input_relative_path": "25.9月 普通个人版/9.1 普通个人版/Jefferies"
      }
    }
  },
  "passages": [
    {
      "passage_id": "cfa5053bac699edc",
      "text": "Australia | Insurance",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "3c60e3e77076ad2f",
      "text": "Equity ResearchAugust 28,2025",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "8f25a221c049b264",
      "text": "MPL won't back down from giving back with a final, increased customer giveback. Resident and non-resident policyholder growth, increased contribution from Medibank Health and higher investment returns see MPL's underlying NPAT increase 8.5%. In FY26E, MPL expect moderating industry growth and increased resident claiming rates whilst pressure continues for the private hospital sector. Retain Hold, PT up to A&#36;5.40 (from A&#36;4.80).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "0a0a964d84d1151b",
      "text": "**FY25** **again** **sees** **positive** **net** **growth** **in** **resident** **and** **non-resident** **policyholders.** MPL saw net resident policy growth of 1.4% on pcp (vs JEF 0.7%) and higher margin, non-resident policy unit growth of 3.1% (vs JEF at 5.8%). Average claims per policy unit grew 2.2% (vs guidance of 2.4-2.6%, JEF at 2.6%). FY25 underlying NPAT increased 8.5% on pcp to A&#36;619m (vs FactSet cons A&#36;607m, JEF at A&#36;621m), driven by resilient policy growth, better-than-expected claims inflation and effective margin management.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "49e043fa017850f5",
      "text": "**FY26E** **guidance.** Management aim to grow market share of resident health insurance despite moderating system growth. Resident claims per policy unit are expected to grow by 2.6-2.9%. Non-resident gross profit is expected to grow. Low-double-digit organic growth is expected for Medibank Health. Cybercrime costs of cA&#36;35m are forecast.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "e2fab35c596840bd",
      "text": "**MPL's** **better-than-system** **lapse** **rates** **provide** **advantage** **against** **ongoing** **competitive** **intensity.** Industry analysis suggests longer-tenured policyholders typically generate higher gross margins and lower claims, and this is in addition to the benefit of fewer acquisition costs.MPL's rigour around retaining and attracting policyholders enables efficient growth which will be of increasing advantage as some competitive behavior becomes unsustainable.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "bd1c1c7b1f2f4cca",
      "text": "**Growing** **hospital** **utilization,** **as** **well** **as** **increased** **bed** **rates** **in** **NSW** **and** **newly** **renegotiated** **private** **hospital** **agreements,** **should** **drive** **up** **claiming** **rates** **in** **FY26E.** Surgical claims will grow in line with hospital utilization. Non-surgical claims, including mental health and rehabilitation, have continued below historical expectations. Although improved, healthcare staffing remains constrained. We will watch for hospital and extras utilization patterns as consumers seek value from their cover and hospital resourcing recovers.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d8c39ce2b111254f",
      "text": "**MPL** **Underlying** **NPAT** **decreases** **2.2%** **in** **FY26E** **and** **2.4%** **in** **FY27E.** Changes to our FY26E forecasts include, 1)health insurance policy unit growth of 1.4% (from 1.5%); 2) Net resident claims/policy unit growth of 2.7% (from 2.6%); 3) Health insurance management expenses of A&#36;687m (from A&#36;677m), and 4) Net investment income of A&#36;178m (from A&#36;155m)",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "8c8d1ffb39a1246f",
      "text": "**PT** **&#36;5.40** (from A&#36;4.80). We also update comparable multiples, which have increased. MPL's FY25 NPAT beat consensus with increased policies, steady claims growth and disciplined cost management. However, with expectations for slower industry growth and higher claims for resident policies, we expect more challenges in FY26E for the industry and for MPL, and wonder if the government will act to support private hospitals.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "c6a6629f5a3ce7ac",
      "text": "FY(Jun)2025A2026E2027E2028EEPS0.180.230.250.27Rev.(MM)8,604.09,077.39,610.810,173.0Operating Profit(MM)762.4586.0866.2915.6Adj Net Profit501636689737",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "bb1a36380f0721fe",
      "text": "TARGET|ESTIMATE CHANGERATINGHOLDPRICEAUD5.02*PRICE TARGET|% TO PT↑AUD5.40(AUD4.80)|+8%52W HIGH-LOWAUD5.31-AUD3.53FLOAT(%)|ADV MM (USD)99.9%|25.06MARKET CAPAUD13.8B|$9.0BTICKERMPL AU",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "62c3b166963fa39d",
      "text": "*Prior trading day's closing price unless otherwise noted.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "c1d901ded5c87665",
      "text": "FY(Jun)CHANGE TO JEFEJEF vs CONS20262027 2026 2027REV+1%+2% NM +1%EPS-2%-2% -2% +1%2026(AUD)1Half2Half FYEPS0.080.15 +0.23PREV0.24",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "58bc32e96a0d90ef",
      "text": "Figure 1-Medibank Private - Share price chart",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "8ac5bfbeb1a2655a",
      "text": "Figure 2-Medibank Private - P/E band chart",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "8cf279bd630ead93",
      "text": "Source: Company data, FactSet, JEF estimates",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "4492714623d19fd2",
      "text": "**David Stanton, MD*|Equity Analyst**",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "3fc13b297b112aab",
      "text": "**Simon Fitzgerald*|Equity Analyst**",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "6bb107c6f1b76a64",
      "text": "MPL provides a defensive investment opportunity with a market- leading position of c.27% share, positive upside to rising interest rates, strong balance sheet with no debt, and the bulk of policyholders deem health insurance a necessity.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "f6c6d3e3fa19cf3d",
      "text": "Risk/Reward - 12 Month View",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "42e3686cb13f0824",
      "text": "For MPL, our base case is based on an equally weighted blend of DCF and capitalisation of normalised P/E and P/BV multiples and assumes a market share of \\(27.1\\%\\) going forward with average premium inflation of \\(2.7\\%\\) pa and claims inflation of \\(2.7\\%\\) pa for the health insurance business.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "6bb6c96fd87d9f5c",
      "text": "Our upside scenario for MPL is based on an equally- weighted blend of DCF and capitalisation of normalised PE and P/BV multiples and assumes a market share of \\(27.6\\%\\) going forward with average premium inflation of \\(2.9\\%\\) pa and claims inflation of \\(2.7\\%\\) pa for the health insurance business.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "252d81152ca08bdc",
      "text": "Our downside scenario for MPL is based on an equally- weighted blend of DCF and capitalisation of normalised PE and P/BV multiples and assumes a market share of \\(26.6\\%\\) going forward with average premium inflation of \\(2.5\\%\\) pa and claims inflation of \\(2.9\\%\\) pa for the health insurance business.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "41128004dd4f41de",
      "text": "Private Health Insurance inherently creates social benefit by reducing the cost of healthcare for customers; further savings mean greater benefit.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "c6dce96557166592",
      "text": "1) Certified carbon neutral (Scope 1, 2 and 3) since 2019. Committed to Net Zero by 2040. \n2) MPL targets at least 500,000 customer check-ins; and 2m Health engagement interactions per annum. \n3) MPL targets employee advocacy of \\(+26\\) for products and services and at least \\(1.4\\%\\) of employees identifying as Aboriginal and/or Torres Strait Islander. MPL targets at least \\(40\\%\\) representation of women across leadership position. \n4) Lost time injury frequency rate targets: for Medibank/ahm \\(",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "7e62d9fd80117aa9",
      "text": "(Note: To commemorate the recent passing of founder Brian Wilson, we will be using Beach Boys' songs for our note titles in this reporting season.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "f5ab1849c2023e94",
      "text": "Figure 3 - Medibank Private - Expanded Summary Table (ASm)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "48ecdbf574f919a2",
      "text": "Year-end 30 Jun (ASm)FY24AFY25AFY26EFY27EFY28ETotal Revenue8,1768,6049,0779,61110,173Total operating profit700762586866916Net investment income182208178157177Reported Profit493501636689737Underlying Profit570619636689737JEF Adj NPAT/consensus100%100%99%102%107%Normalised EPS (A&amp;amp;c)17.918.223.125.026.8Consensus EPS (A&amp;amp;c)13.016.023.124.424.9DPS (A&amp;amp;c)16.618.019.020.021.0Dividend yield (%)3.33.63.84.04.2FD normalised P/E (x)20.927.821.720.118.8Price/book (x)4.56.05.55.24.8ROE (%)21.421.425.425.525.4Net debt/equity (%)net cashnet cashnet cashnet cashnet cash",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "63b5dbb1ed3bc423",
      "text": "Source: Company data, JEF estimates, FactSet",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "5cd19f51a75bd057",
      "text": "Resident and non- resident policyholder growth, increased contribution from Medibank Health and higher investment returns see MPL's underlying NPAT increase \\(8.5\\%\\) . In FY26E, MPL expect moderating industry growth and increased resident claiming rates at the same time as pressure continues for the private hospital sector.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "d9d09a3587584542",
      "text": "MPL saw net resident policy growth of \\(1.4\\%\\) on pcp (vs JEF \\(0.7\\%\\) ) and higher margin, non- resident policy unit growth of \\(3.1\\%\\) (vs JEF at \\(5.8\\%\\) ). Average claims per policy unit grew \\(2.2\\%\\) (vs guidance of \\(2.4 - 2.6\\%\\) , JEF at \\(2.6\\%\\) ). FY25 underlying NPAT increased \\(8.5\\%\\) on pcp to A\\$619m (vs FactSet cons A\\$607m, JEF at A\\$621m), driven by resilient policy growth, better- than- expected claims inflation and effective margin management.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "76336b22cc3512e7",
      "text": "For the full year, management aim to grow market share of resident health insurance despite moderating system growth. Resident claims per policy unit are expected to grow by \\(2.6 - 2.9\\%\\) . Non- resident gross profit is expected to grow. Low- double- digit organic growth is expected for Medibank Health. Cybercrime costs of cA\\$35m are forecast.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "ac1c7a4730d6cff9",
      "text": "Differences compared to our forecasts include: 1) Higher- than- expected Gross Profit; 2) Higher- than- expected Net investment income, and 3) Lower- than- expected adjusted NPAT.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "c3b41230d5f5e4a3",
      "text": "Changes to our FY26E forecasts include: 1) Health insurance policy unit growth of \\(1.4\\%\\) (from \\(1.5\\%\\) ); 2) Net resident claims/policy unit growth of \\(2.7\\%\\) (from \\(2.6\\%\\) ); 3) Health insurance management expenses of A\\$687m (from A\\$677m), and 4) Net investment income of A\\$178m (from A\\$155m). Consequently, we reduce underlying NPAT by \\(2.2\\%\\) in FY26E and \\(2.4\\%\\) in FY27E.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "c780d4f9057874c7",
      "text": "Figure 4 - Medibank - Changes to forecasts",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "944dbd687992cb3f",
      "text": "FY25AFY26EFY27EFY28EASmPrevRevDiff (%)PrevRevDiff (%)PrevRevDiff (% )PrevRevDiff (%)Revenue8,589.58,604.00.28,983.210,977.31.09,424.79,610.82.09,887.210,173.02.9Gross profit1,649.01,672.91.41,509.51,551.62.81,902.01,902.70.02,038.92,029.3(0.5)Management expenses(840.2)(847.2)(894.4)(908.1)(955.8)(977.3)(1,022.7)(1,052.8)Operating profit762.4586.0Net investment income190.9207.88.8155.4178.014.5150.0157.24.8159.211.2Underlying NPAT621.1618.7(0.4)651.0636.4(2.2)706.2689.1(2.4)760.673.3EPS (c)22.618.2(19.4)23.623.1(2.2)25.625.0(2.4)27.626.8DPS (c)18.018.00.019.019.00.021.020.0(4.8)22.021.0Net op cashflow1,116.0514.1(53.9)1,134.61,024.7(9.7)1,482.01,501.01.31,589.11,598.0",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "96f4db269ed5f1cb",
      "text": "Source: Company data, JEF estimates",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "22d656a20ccdc4aa",
      "text": "Goals for FY26E include:",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "0223c51f6249f926",
      "text": "- Grow market share of resident policyholders in a disciplined way, including further volume growth in the Medibank brand, with industry growth expected to moderate relative to FY25.- Net resident claims per policy unit growth of \\(2.6\\% - 2.9\\%\\) .- Productivity savings of A\\$10m.- Cybercrime costs expected to be cA\\$35m.- Low-double-digit organic operating profit growth is expected for Medibank Health.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "937a51d7b3e51a22",
      "text": "- MPL Group revenue from external customers \n- Increased \\(5.2\\%\\) on pcp to A\\$8.6bn (from A \\(8.2bn in FY24), with solid growth in resident policyholders.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "bfc646b2ee76cf5d",
      "text": "Figure 5 - Segment operating profit FY26E",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "f36a216bbe2e8fba",
      "text": "Source: JEF estimates",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "a4cec7aefdc8e83a",
      "text": "- Health Insurance (85% of FY26E Operating Profit): FY25 premium revenue increased by \\(4.1\\%\\) to A\\$8.2bn (vs. JEF at A\\$8.2bn). FY25 Gross Profit was A\\$1,396m (vs. JEF at A\\$1,376m), benefiting from MPL's treatment of COVID-19 claims trends. Net resident policyholders increased by 18,500, or \\(0.9\\%\\) on pcp. Policyholders increased by \\(0.3\\%\\) for the Medibank brand and increased by \\(4.3\\%\\) for the ahm brand.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "750e83859a2c0f9f",
      "text": "- Customer acquisition: The health insurance customer acquisition rate was \\(11.5\\%\\) over FY25 (from \\(11.0\\%\\) in FY24), offset by lapse rates of \\(10.1\\%\\) (from \\(10.3\\%\\) in FY24). Competitive intensity remains high. MPL will further differentiate its brands by investing in new products and services.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "eabbddaff72072d4",
      "text": "- Medibank Health (15% of FY26E Operating Profit): Revenue increased \\(34.7\\%\\) to A\\$485m with FY25 gross profit of A\\$277m. Operating margin decreased 40bps to \\(17.4\\%\\) . In FY25, Medibank Health generated \\(23.0\\%\\) organic operating profit growth (excluding MyHealth). MPL further increased their ownership interest in MyHealth to \\(91.13\\) (from \\(90.1\\%\\) ).",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "5b1d076b243f4076",
      "text": "- Investment income: At \\(30^{\\text{th}}\\) June 2025, MPL held investment assets totalling A\\$3.64bn (with Total Assets on Balance Sheet of A\\$4.70bn, up \\(0.3\\%\\) on pcp). In FY25, MPL's investment assets generated an underlying return of \\(5.86\\%\\) , a 9bp increase on pcp.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "7940005d6c8a9da2",
      "text": "Figure 6 - Medibank Private - Investment portfolio asset allocation (FY26E)",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "8456c3a73ee3de83",
      "text": "Source: Company data",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "3e0dc3e8a456956c",
      "text": "- Management expense: MPL's industry-leading underlying management expense ratio for health insurance was \\(8.0\\%\\) in FY25, up 20bp on pcp.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "8802668a50c297ec",
      "text": "In considering the Australian private health insurance industry, we acknowledge its importance in the provision and funding of healthcare, but macro headwinds now follow positive pandemic effects.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "4a765a9f708cf8c1",
      "text": "Private health insurance participation has remained higher for longer than we expected, we assume supported by a continuing priority of health post pandemic, moderate premium increases and protracted public hospital wait lists. At the same time, claims continue to increase, higher competitive intensity heightens policy churn with associated costs, and the insured pool ages. The AIHW reports that in FY24 \\(\\sim 6\\%\\) of patients waited more than a year for an elective procedure, a decrease from \\(\\sim 10\\%\\) in FY23 but still significantly higher than \\(\\sim 3\\%\\) in FY20. More recently, we note that elective surgery wait lists in NSW were \\(\\sim 150\\%\\) higher in 1QFY25 on pcp.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "02dcde2421d41560",
      "text": "We continue to watch participation rates, noting slowing migration, aging dynamics and lower mortgage rates. Insurers have to balance rising claims costs with affordable premiums and membership stability.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "3f0a89e30975d38a",
      "text": "For FY26E, we estimate unitary Australian resident net claims growth for Medibank of \\(2.7\\%\\) on pcp with healthcare resourcing continuing to improve, notwithstanding pronounced staff shortages in particular areas.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "806a7154ae9a7de8",
      "text": "With the increase in NSW bed rates from 1st January 2025, Medibank is guiding to resident claims per policy unit growth of \\(2.6\\% - 2.9\\%\\) in FY26E. Healthcare staff are increasingly available and policyholders are looking for value from their cover at the same time as models of care and healthcare innovation evolve. We will look for the future trajectory of health insurance claims.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "6fa022121979cf76",
      "text": "In October 2024, the DoHAC published their Private Hospital Sector Financial Health Check which indicated: a) a progressive shift from overnight stays to same- day separations, with these shorter stays mostly taken up by overnight hospitals; b) changes in demand for certain services, and c) ongoing challenges around staffing and inflation for the period from FY18 to FY24.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "f394eb66421c60c3",
      "text": "Since then, Healthscope, the second- largest private hospital operator in Australia, has entered administration with indebtedness, COVID- 19 and private health insurers all cited as contributing to the company's failure. In addition, some \\(\\sim 80\\) private hospital services have closed over the past 5 years, at the same time as the opening of other private hospital services.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "cda6c94d140535eb",
      "text": "We have also seen a number of stakeholders comment on the proportion of premiums returned to members, with the Australian Private Hospitals Association asking that insurers pay \\(88\\%\\) of premiums to healthcare providers.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "92a4ba5359aaf6f2",
      "text": "We await further updates from Government and recall Minister Butler's comments in April 2025 saying health funds must 'urgently' work on lifting the percentage of premiums paid to hospitals.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "c534f6c5d9d6881b",
      "text": "Medibank incurred cybercrime costs of \\(\\Delta \\Phi 46.4m\\) in FY23, \\(\\Delta \\Phi 39.8m\\) in FY24 and a further expense of \\(\\Delta \\Phi 39.7m\\) in FY25. FY26E cybercrime costs of \\(\\Delta \\Phi 35m\\) are expected, with FY27E costs expected to be limited to ongoing regulatory investigations and litigation. The Office of the Australian Information Commissioner (OAIC) has commenced litigation against MPL for breach of the Privacy Act. In its concise filing, the OAIC disclosed that MPL had been the victim of hacking since mid- August 2022 with \\(\\sim 520GB\\) of data exfiltrated, including the Medicare and passport numbers of up to 9.7m individuals. Litigation is also underway in the Federal Court through a class action for privacy breach- related loss.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "714a5f7cfd11250e",
      "text": "Persistent costs associated with the October 2022 cyberhack do, however, see Medibank with stronger systems. These proceedings present long tail economic liability risk if complainants are successful in being awarded damages.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "fe23a413766d8368",
      "text": "We enclose MPL's divisional summary in the following figure.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "b6cd6d6090a942f3",
      "text": "Figure 7 - Medibank Private - Divisional Summary",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "ef4481451badb1e8",
      "text": "(A$m)1H24A2H24AFY24A1H25A2H25AFY25A1H25 on 1H24 (%)2H25 on 2H24 (%)FY25 on FY24 (%)Revenue (A$m)Health insurance premium revenue3,898.74,004.37,903.04,085.74,125.38,211.04.83.03.9Medibank Health revenue141.4218.7360.1228.4256.8485.261.517.434.7Management expenses (A$m)Health insurance management expense(298.9)(316.0)(614.9)(312.4)(342.5)(654.9)Medibank Health management expense(45.7)(94.5)(140.2)(90.9)(101.4)(192.3)Gross profit (A$m)Health insurance gross profit615.9691.31,307.2661.6734.81,396.47.46.36.8Medibank Health gross profit73.1131.3204.4131.1145.4276.579.310.735.3Gross margin (%)Health insurance6.35.86.06.25.65.9(15)(18)(17)Medibank Health1.91.71.81.71.81.8(19)10(1)Management expense ratio (%)Health insurance7.77.97.87.68.38.0(2)4120Medibank Health32.343.238.939.839.539.6748(372)70Net margin (%)Health insurance6.86.26.56.66.16.3(17)(17)(17)Medibank Health2.62.42.42.42.52.5(12)80",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "d121c2854fbb0346",
      "text": "Source: Company data, JEF estimates",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "44a53b29eae82a4b",
      "text": "We enclose MPL's result summary in the following figure.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "1c012e58d73b9a77",
      "text": "Figure 8 - Medibank - Income Statement (A\\$m)",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "15484c28d693ee27",
      "text": "Income Statement (A$m)1H24A2H24AFY24A1H25A2H25AFY25A1H25 on 1H24 (%)2H25 on 2H24 (%)FY25 on FY24 (%)Revenue4,024.04,151.88,175.84,270.74,333.38,604.06.14.45.2Other revenue0.00.00.00.00.000.0Health insurance net claims expense(3,309.4)(3,286.4)(6,595.8)(3,323.1)(3,491.5)(6,814.6)Gross profit689.0822.61,511.6830.4842.51,672.920.52.410.7Management expenses(344.6)(410.5)(755.1)(403.3)(443.9)(847.2)Segment operating profit343.7409.0752.7386.8431.4818.212.55.58.7Corporate overheads(24.3)(28.6)(52.9)(26.7)(29.1)(55.8)Total operating profit319.4380.4699.8360.1402.3762.412.75.88.9Amortisation of intangibles0.00.00.00.00.000.0Other income/(expenses)(26.4)(33.1)(59.5)(25.2)(33.4)(58.6)Profit before net investment income and tax293.0347.3640.3334.9368.9703.814.36.29.9Net investment income83.698.6182.2114.593.3207.837.0(5.4)14.1Profit before tax491.9219.8711.7493.0235.8728.80.27.32.4Taxation(148.7)(66.6)(215.3)(148.9)(70.6)(219.5)Profit After Tax343.2153.2496.4344.1165.2509.30.37.82.6Adjusted Economic Profit343.2149.3492.5340.3160.5500.8(0.8)7.51.7Reported profit343.2149.3492.5336.5164.3500.8(2.0)10.01.7Underlying profit262.5307.9570.4294.9323.8618.712.35.28.5Per shareNormalised EPS (cps)12.55.417.912.45.818.2(0.8)7.51.7DPS (cps)7.29.416.67.810.218.08.38.58.4Average shares (mn)2,754.02,754.02,754.02,754,02,754.02,754.00.00.00.0Book value per share (cps)74.278.278.280.083.883.87.87.27.2Tangible book value per share (cps)73.666.766.769.366.766.7(5.8)(0.1)(0.1)Ratio analysis (%)Diff (bp)Diff (bp)Diff (bp)Gross margin17.119.818.519.419.419.4232(37)95Net margin7.99.28.68.49.38.9491230Management expense ratio8.59.79.19.310.19.7824160Return on equity (Reported profit)15.96.621.714.27.121.6(165)52(7)Return on equity (Underlying profit)12.113.525.112.514.026.73242158Effective tax rate30.230.330.330.229.930.1(3)(36)(13)",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "a8b02cddeda23e51",
      "text": "Source: Company data, JET estimates",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "906c865aa9db7a58",
      "text": "Changes to our MPL forecasts include:",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "3be3d46111d2747b",
      "text": "Revenue: In FY26E, we assume Total Revenue of A\\$9.1bn (from A\\$9.0bn).- Health insurance net claims expense: We have assumed health insurance net claims expenses will be A\\$7.4bn in FY26E (from A\\$7.3bn).- Management expense: We assume Total management expenses of A\\$908m in FY26E (from A\\$894m).- Investment income: In FY26E, we assume a weighted average investment return of \\(5.2\\%\\) .- Tax expense: We have assumed an effective tax rate for FY26E of \\(30.3\\%\\) (unchanged).- Payout ratio: Our assumed dividend payout ratio is \\(80\\%\\) , implying a FY26E total dividend of A\\$0.19.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "f3b1ca4287db9e96",
      "text": "We update comparable multiples, which have increased. Consequently, we increase our price target for MPL to A\\\\$5.40. We use an equally weighted blended valuation of DCF, P/E, and P/BV per share multiples.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "c1a060b3ac6439eb",
      "text": "Based on a \\(4\\%\\) risk- free rate, \\(8.4\\%\\) COE and \\(8.4\\%\\) WACC, the DCF component of our valuation is A \\(3.65\\) (up from A\\\\$4.07), normalised P/E multiple of 29.6x FY2 EPS (from 23.5x) and P/BV multiple of 5.0x FY2 P/BV (from 4.1x). The multiples we have used as a relative benchmark are NIB Holdings, UnitedHealth Care Inc, and Elevance Health Inc.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "6471888a5267053d",
      "text": "Figure 9 - Medibank Private - Valuation methodology (A\\$ per share)",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "6baaa15ae9c8bd3b",
      "text": "MetricWeight (%)Valuation (A$ps)Weighted valuation (A$15:1)DCF Valuation (12 month forward)33.33.651.22P/E Valuation* at (29.6x FY2)33.37.632.54P/BV Valuation* at (5x FY2)33.34.931.64Blended Equity Valuation (A$ps)100.05.40Price Target (A$ps) (rounded)5.40",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "65743e1d35c6fdf3",
      "text": "Source:JEF estimates,FactSet",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "8ebdb0b468ea585d",
      "text": "Using our new EPS assumptions, on a 12- month- forward P/E basis, MPL is trading at 21.4x. This is \\(c5\\%\\) above its historical mean of 20.3x.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "a4cbc4ce079d2ff1",
      "text": "Figure 10 - Medibank Private - P/E band chart",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "d982294ca6c74d94",
      "text": "Source: Company data, FactSet, JEF estimates",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "b7c5d93505c63f43",
      "text": "Figure 11 -Medibank Private -Financial Summary (A\\\\$m)",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "71b97d8d5f838887",
      "text": "Figure 11 - Medibank Private - Financial Summary (A$m)Year-end 30 JunFY24AFY25AFY26EFY27EFY28EValuation metrics Method: DCF/PE/EV/EBITDAShare price (A$)5.02Income statement (A$m)Target price (A$)5.40Total Revenue8,1768,6049,0779,61110,173DCF valuationUpside/(Downside) to TP8%Health insurance net claims expense(6,596)(6,815)(7,380)(7,528)(7,924)Rf (%)4.0DCF Valuation (USD)3.65Medibank Health cost of services(68)(117)(146)(180)(220)Rm-Rf (%)5.5Gross profit1,5121,6731,5521,9032,029Beta0.8Management expenses(755)(847)(908)(977)(1,053)Ke = (Rf + Beta(Rm-Rf))8.4(A$m)Corporate overheads(53)(56)(57)(59)(61)Equity (E/EV)100.0NPV of cash flow8,659Total operating profit700762586866916Debt (D/EV)0.0Add: Investments0Profit before net investment income640704523833882Interest rate (Kd)5.0Less: Net debt-619Net investment income182208178157177Tax rate (t)30.0Less: Minority0.78Profit before tax7127299299901,059WACC8.4DCF Equity value9,278Taxation(215)(220)(281)(289)(309)Multiples (x)FY24AFY25AFY26EProfit After Tax496509647701750FD normalised P/E20.927.821.7Adjusted Economic Profit493501636689737FD normalised P/EGrth0.416.50.8Abnormals &amp; Other Items (net of Reported Profit493501636689737Reported P/E20.927.821.7Underlying Profit570619636689737Price/cashflow10.427.113.5Shares (m)2,7542,7542,7542,7542,734Price/book4.56.05.5Per share (A$ c)EV/Sales1.21.51.4Normalised EPS1818232527Dividend yield (%)3.33.63.8Book value per share949297102107FD multiples at target price (x)Tangible book value per share6767727884FD norm. P/E at price target30.229.723.4Net Tangible assets per share62.562.772.178.084.2Ratio at price target6.46.46.0DPS1718192021Ratio analysis (%)FY24AFY25AFY26ECashflow (A$m)FY24AFY25AFY26EFY27EFY28ENet profit margin18.519.417.1Receipts8,1578,3629,1719,70710,271Management expense ratio6.05.87.0Payments(7,156)(5,581)(8,405)(8,648)(9,157)Effective tax rate7.88.08.0Tax Paid(132)(241)(281)(289)(309)Dividend payout30.330.130.3Net cash from operating activity8693818891,3621,460ROE92.899.082.2Interest received120133136139138ROA (pretax)21.421.425.4Operating Cashflow - post int &amp; Free Cash Flows to Equity9885141,0251,5011,598Loss ratio17.818.021.8Investment expenses(5)(6)(8)(9)(9)Expense ratio80.779.281.3Net proceeds from sale of finance(116)6311289111Growth rate (%)91.491.193.5Other net cash from investing(103)(69)000Revenue4.75.25.5Net cash from investing activities(104)122241220240Gross profit11.810.77.2Other Financing Cash Flow(56)(53)000Management expenses4.02.50.0Cash Dividends Paid(430)(481)(501)(551)(578)Adjusted NPAT59.61.727.1Net cash from financing activities(486)(534)(501)(551)(578)Normalised FDPS59.61.727.1Net Proceeds from Borrowings(1)0000Segmental revenue (A$m)FY24AFY25AFY26ENet increase/(decrease) in cash270(42)6281,0311,122Health insurance premium revenue (after C-7,9038,2118,613Balance sheet (A$m)FY24AFY25AFY26EFY27EFY28EMedibank Health revenue360485558Cash &amp; equivalents691649717765814Consolidation(87)(92)(94)Accounts receivable4066707479Other revenue000Inventories3,0483,0633,3863,6113,844Segmental Op Profit (A$m)Other current assets2834363840Health insurance692742547Total current assets3,8063,8124,2104,4884,777Medibank Health648497LT investments00000Corporate overheads(53)(56)(57)Fixed assets205194194194194Segmental Op Profit growthIntangible assets467500524552580Health insurance7.1%-26.3%48.9%Other LT assets207195515457Medibank Health31.2%15.0%15.0%Total assets4,6854,7004,9795,2885,609Corporate overheadsnananaAccounts payable145171180190202Key segment metricsFY24AFY25AFY26ECurrent claims liabilities1,6361,6061,6851,7731,865Health insurance5,1065,1985,268Current Unearned premium liabil00000PSEUs (#'000s)2.00.00.0Other current liabilities233227227227227Average PSEU growth (%)4.03.94.9Total current liabilities2,0152,0042,0922,1912,293Premium growth (%)3.43.38.3Non-current payables170180190201213Net claims growth (%)1,5481,5801,635Non-current Unearned premium00000Revenue per (average) PSEU (A$)1,5481,5801,635Long term other liabilities195180187196204Net claims per (average) PSEU (A$)(1,292)(1,311)(1,358)Total liabilities2,3802,3642,4692,5882,711Medibank HealthMinority interest &amp; Convertible c(1)0112335Revenue growth (%)34.715.015.0Shareholders funds8585858585Cost of services (A$m)(68)(117)(146)Retained earnings2,0682,2242,3862,5652,751Level range &amp; CapitalOther reserves15227272727Current ratio (x)0.00.00.0Other equity(1)0112335Net debt/Net debt + equity (%)net cashnet cashnet cashTotal shareholders' equity2,3052,3362,5102,7002,898(Health insurance (Net cash capital)/[Next 12m prem)14.1%13.9%13.8%Total equity &amp; liabilities4,6854,7004,9795,2885,609Solvency ratio1.631.561.58Net tangible assets1,8381,8361,9852,1492,318Total tangible and liquid assets1,8881,8701,9852,1492,318",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "465e0b15d29d604f",
      "text": "Source: Company data, JEF estimates",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "b7910afe0ef471a7",
      "text": "MedibankMedibank Private Limited (MPL) underwrites and distributes private health insurance policies through the Medibank and ahm brands. MPL operates two businesses - Health Insurance, and Medibank Health. The Health Insurance segment offers private health insurance products including hospital cover and ancillary cover, as stand- alone products and packaged products. The Medibank Health segment offers a range of activities including contracting with government and corporate customers to provide health management services, as well as providing a range of telehealth services in Australia.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "240645fe03da5931",
      "text": "Key risks for Australian private health insurers: 1) rising interest rates; 2) historically declining participation rates, especially for younger people; 3) regulatory reform around community rating, incentivising cover or selection of policyholders; 4) treatment expansion as medical technology advances and Australia's population ages; 5) consumer perceptions of the value of private health insurance; 6) mispricing of insurance products given very limited ability to select policyholders.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "668e55127effbc61",
      "text": "Downside risks for Medibank Private: 1) market share growth given MPL's leading position; 2) estimation of permanent net savings due COVID- 19; 3) volatility of investment income.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "965b1c49a19e8f22",
      "text": "Upside risks for Medibank Private: 1) better- than- expected investment income; 2) XXcreased participation rates during the pandemic persists in future; 3) consumer perceptions are boosted by MPL's emphasis on wellbeing.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "7beddcd663e1a483",
      "text": "(Article 3(1)e and Article 7 of MAR) Recommendation Published Recommendation Distributed",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "a7b6035c62cd7bf3",
      "text": "August 28, 2025 11:46 A.M. August 28, 2025 11:46 A.M.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "5a7283afd21447db",
      "text": "Buy - Describes securities that we expect to provide a total return (price appreciation plus yield) of \\(15\\%\\) or more within a 12- month period. Hold - Describes securities that we expect to provide a total return (price appreciation plus yield) of plus \\(15\\%\\) or minus \\(10\\%\\) within a 12- month period. Underperform - Describes securities that we expect to provide a total return (price appreciation plus yield) of minus \\(10\\%\\) or less within a 12- month period. The expected total return (price appreciation plus yield) for Buy rated securities with an average security price consistently below \\(10\\) or more within a 12- month period as these companies are typically more volatile than the overall stock market. For Hold rated securities with an average security price consistently below \\(10\\) , the expected total return (price appreciation plus yield) is plus or minus \\(20\\%\\) within a 12- month period. For Underperform rated securities with an average security price consistently below \\(10\\) , the expected total return (price appreciation plus yield) is minus \\(20\\%\\) or less within a 12- month period.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "b61f1a8ace8fbc0e",
      "text": "NR - The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Jefferies policies.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "58b4e2ac6e231832",
      "text": "CS - Coverage Suspended. Jefferies has suspended coverage of this company.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "510c255294c8a14f",
      "text": "NC - Not covered. Jefferies does not cover this company.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "14ee32a27999d9e8",
      "text": "Restricted - Describes issuers where, in conjunction with Jefferies engagement in certain transactions, company policy or applicable securities regulations prohibit certain types of communications, including investment recommendations.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "6c0b120941e83d32",
      "text": "Monitor - Describes securities whose company fundamentals and financials are being monitored, and for which no financial projections or opinions on the investment merits of the company are provided.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "fea628c5bdbeed2c",
      "text": "Jefferies methodology for assigning ratings may include the following: market capitalization, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "fea65d637f7c86bc",
      "text": "Jefferies Franchise Picks include stock selections from among the best stock ideas from our equity analysts over a 12 month period. Stock selection is based on fundamental analysis and may take into account other factors such as analyst conviction, differentiated analysis, a favorable risk/reward ratio and investment themes that Jefferies analysts are recommending. Jefferies Franchise Picks will include only Buy rated stocks and the number can vary depending on analyst recommendations for inclusion. Stocks will be added as new opportunities arise and removed when the reason for inclusion changes, the stock has met its desired return, if it is no longer rated Buy and/or if it triggers a stop loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a \\(15\\%\\) stop loss, and the remainder will have a \\(20\\%\\) stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not sector based, but we may note where we believe a Pick falls within an investment style such as growth or value.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "ae8065ffaadac3f3",
      "text": "Medibank Private Limited (MPL AU: AUD5.02, HOLD)",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "5cfba3dff53a7c93",
      "text": "Rating and Price Target History for: Medibank Private Limited (MPL AU) as of 08-27-2025",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "7fd4673f9fe507b7",
      "text": "Notes: Each box in the Rating and Price Target History chart above represents actions over the past three years in which an analyst initiated on a company, made a change to a rating or price target of a company or discontinued coverage of a company. Legend:",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "eaa2f078d23b3237",
      "text": "I: Initiating Coverage \nD: Dropped Coverage \nB: Buy \nH: Hold \nUP: Underperform",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "d3b20ac90b05fa7c",
      "text": "Distribution of Ratings",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "5e7f3e6bea449acc",
      "text": "CountPercentCountPercentCountPercentBUY211260.69%36717.38%1175.54%HOLD121134.80%1058.67%221.82%UNDERPERFORM1574.51%31.91%31.91%",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "e46d2cc855d67bc6",
      "text": "Jefries does busines and seeks to do busines with companies covered in its research reports, and expects to receive or intends to seek compensation for investment banking services among other activities from such companies. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Jefferies Equity Research refers to research reports produced by analysts employed by one of the following Jefferies Financial Group Inc. (Jefferies) companies:",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "c5649e760bc1b500",
      "text": "United States: Jefferies LLC which is an SEC registered broker- dealer and a member of FINRA (and distributed by Jefferies Research Services, LLC, an SEC registered Investment Adviser, to clients paying separately for such research).",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "52240f745afedd06",
      "text": "Canada: Jefferies Securities Inc., which is an investment dealer registered in each of the thirteen Canadian jurisdictions and a dealer member of the Canadian Investment Regulatory Organization, including research reports produced jointly by Jefferies Securities Inc. and another Jefferies entity (and distributed by Jefferies Securities Inc.).",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "f0d50cb3b607e3e9",
      "text": "Where Jefferies Securities Inc. distributes research reports produced by Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch or Jefferies India Private Limited, you are advised that each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited operates as a dealer in your jurisdiction under an exemption from the dealer registration requirements contained in National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations and, as such, each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited is not required to be and is not a registered dealer or adviser in your jurisdiction. You are advised that where Jefferies LLC or Jefferies International Limited prepared this research report, it was not prepared in accordance with Canadian disclosure requirements relating to research reports in Canada.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "7a75cc9764ff1088",
      "text": "United Kingdom: Jefferies International Limited, which is authorized and regulated by the Financial Conduct Authority, registered in England and Wales No. 1978621; registered office: 100 Bishopsgate, London EC2N 4JL; telephone +44 (0)20 7029 8000; facsimile +44 (0)20 7029 8010.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "a02b6a76b20b2b8d",
      "text": "Japan: Jefferies (Japan) Limited, Tokyo Branch, which is a securities company registered by the Financial Services Agency of Japan and is a member of the Japan Securities Dealers Association; located at Tokyo Midtown Hibiya 30F Hibiya Mitsui Tower, 1- 1- 2 Yurakucho, Chiyoda- ku, Tokyo 100- 0006; telephone +813 5251 6100; facsimile +813 5251 6101.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "c2f945972e1d68a3",
      "text": "Australia: Jefferies (Australia) Pty Limited (ACN 623 059 898), which holds an Australian financial services license (AFSL 504712) and is located at Level 20, 60 Martin Place, Sydney NSW 2000; telephone +61 2 9364 2800.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "3b56b8c474704c05",
      "text": "Dubai: Jefferies International Limited, Dubai branch, which is licensed by the Dubai Financial Services Authority (DFSA Reference Number F007325); registered office Unit L31- 06, L31- 07, Level 31, ICD Brookfield Pace, DIFC, PO Box 121208, Dubai, UAE.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "32f67e5dc352fe1d",
      "text": "This report was prepared by personnel who are associated with Jefferies (Jefferies Securities Inc., Jefferies International Limited, Jefferies GmbH, Jefferies Hong Kong Limited, Jefferies Singapore Limited, Jefferies (Japan) Limited, Tokyo Branch, Jefferies India Private Limited), and Jefferies (Australia) Pty Ltd; or by personnel who are associated with both Jefferies LLC and Jefferies Research Services LLC (\"JRS\"). Jefferies LLC is a US registered broker- dealer and is affiliated with JRS, which is a US registered investment adviser. JRS does not create tailored or personalized research and all research provided by JRS is impersonal. If you are paying separately for this research, it is being provided to you by JRS. Otherwise, it is being provided by Jefferies LLC. Jefferies LLC, JRS, and their affiliates are collectively referred to below as \"Jefferies\". Jefferies may seek to do business with companies covered in this research report. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only one of many factors in making their investment decisions. Specific conflict of interest and other disclosures that are required by FINRA, the Canadian Investment Regulatory Organization and other rules are set forth in this disclosure section.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "5b70733e31d1ba05",
      "text": "If you are receiving this report from a non- US Jefferies entity, please note the following: Unless prohibited by the provisions of Regulation S of the U.S. Securities Act of 1933, as amended, this material is distributed in the United States by Jefferies LLC, which accepts responsibility for its contents in accordance with the provisions of Rule 15a- 6 under the US Securities Exchange Act of 1934, as amended. Transactions by or on behalf of any US person may only be effected through Jefferies LLC. In the United Kingdom and European Economic Area this report is issued and/or approved for distribution by Jefferies International Limited (\"JIL\") and/or Jefferies GmbH and is intended for use only by persons who have, or have been assessed as having, suitable professional experience and expertise, or by persons to whom it can be otherwise lawfully distributed. Jefferies LLC, JIL, Jefferies GmbH and their affiliates, may make a market or provide liquidity in the financial instruments referred to in this report; and where they do make a market, such activity is disclosed specifically in this report under \"company specific disclosures\".",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "6b30a94386613a37",
      "text": "For Canadian investors, this material is intended for use only by professional or institutional investors. None of the investments or investment services mentioned or described herein is available to other persons or to anyone in Canada who is not a \"permitted client\" as defined by National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations, as applicable. This research report is a general discussion of the merits and",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "3f962e0411598039",
      "text": "first considering whether any advice or recommendation in this report is suitable for the recipient based on the recipient's particular circumstances and, if appropriate or otherwise needed, seeking professional advice, including tax advice. Jefferies does not perform any suitability or other analysis to check whether an investment decision made by the recipient based on this report is consistent with a recipient's investment objectives, portfolio holdings, strategy, financial situation, or needs.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "39f48e79132c82aa",
      "text": "By providing this report, neither JRS nor any other Jefferies entity accepts any authority, discretion, or control over the management of the recipient's assets. Any action taken by the recipient of this report, based on the information in the report, is at the recipient's sole judgment and risk. The recipient must perform his or her own independent review of any prospective investment. If the recipient uses the services of Jefferies LLC (or other affiliated broker- dealers), in connection with a purchase or sale of a security that is a subject of these materials, such broker- dealer may act as principal for its own accounts or as agent for another person. Only JRS is registered with the SEC as an investment adviser; and therefore neither Jefferies LLC nor any other Jefferies affiliate has any fiduciary duty in connection with distribution of these reports.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "b8b68ea52524afd0",
      "text": "The price and value of the investments referred to herein and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "3bccfd2b915c54d3",
      "text": "This report may contain forward looking statements that may be affected by inaccurate assumptions or by known or unknown risks, uncertainties, and other important factors. As a result, the actual results, events, performance or achievements of the financial product may be materially different from those expressed or implied in such statements.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "74c8afd175ef48e9",
      "text": "This report has been prepared independently of any issuer of securities mentioned herein and not as agent of any issuer of securities. No Equity Research personnel have authority whatsoever to make any representations or warranty on behalf of the issuer(s). Any comments or statements made herein are those of the Jefferies entity producing this report and may differ from the views of other Jefferies entities.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "e0686f27d457b120",
      "text": "This report may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor's, and information derived from third- party or proprietary generative artificial intelligence (Gen AI) models. Jefferies does not guarantee the accuracy, completeness, timeliness or availability of this information, and is not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Neither Jefferies nor any third- party content providers, including providers of Gen AI models, give any express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Neither Jefferies nor any third- party content provider shall be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs,",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "78aa07da7a814ccc",
      "text": "expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase, hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "0d1f755b24f9ed6b",
      "text": "Jefferies research reports are disseminated and available electronically, and, in some cases, also in printed form. Electronic research is simultaneously made available to all clients. This report or any portion hereof may not be copied, reprinted, sold, or redistributed or disclosed by the recipient or any third party, by content scraping or extraction, automated processing, or any other form or means, without the prior written consent of Jefferies. Any unauthorized use is prohibited. Neither Jefferies nor any of its respective directors, officers or employees, is responsible for guaranteeing the financial success of any investment, or accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this report or its contents. Nothing herein shall be construed to waive any liability Jefferies has under applicable U.S. federal or state securities laws.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "d757d6776034b900",
      "text": "For Important Disclosure information relating to JRS, please see https://adviserinfo.sec.gov/lAPD/Content/Common/crd_iapd_Brochure.aspx? BRCHR_VRSN_ID=483878 and https://adviserinfo.sec.gov/Firm/292142 or visit our website at https://javatar.bluematrix.com/sellside/Disclosures.action, or www.jefferies.com, or call 1.888. JEFFERIES.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "0448e19564d5e270",
      "text": "\\(①\\) 2025 Jefferies",
      "page": 14,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "0f5f1a81d74ab4cf",
      "name": "Adj Net",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ef914c751b694c24",
      "name": "Adjusted Economic",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8312b1152d37b3fb",
      "name": "Adjusted NPAT",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "146914ba3f2b493a",
      "name": "Australian Healthcare",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "007b87b11bac19c6",
      "name": "Australian Information",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "abba1e271c9fcc77",
      "name": "Australian Private",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "2351ab1d47df8971",
      "name": "Average PSEU",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "2d553ca05ddce2a2",
      "name": "BV Valuation",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "fa37187d417c4d09",
      "name": "Back Down",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "b7c729c0e2366001",
      "name": "Balance Sheet",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "091ea27f0512d847",
      "name": "Base Case",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "90a0c1cb6b7a436e",
      "name": "Beach Boys",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "75b13d4b532b8fb4",
      "name": "Blended Equity",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "582a2d84addf2c93",
      "name": "Brian Wilson",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7860a2554c61a53f",
      "name": "Canadian Investment",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "9279eff4ec685a5f",
      "name": "Cash Dividends",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "dc62425edd02dcb2",
      "name": "Cash Flow",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "9f44d174e8569c96",
      "name": "Catalysts\n\nUnexpected",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6e4788dbad025b7b",
      "name": "Company Description",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a92ba89b9eff6c1b",
      "name": "Company Target",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "bar",
        "title": "2022年中国新能源汽车销量及预测",
        "page": 1,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "1月",
              "2月",
              "3月",
              "4月",
              "5月",
              "6月",
              "7月",
              "8月",
              "9月",
              "10月",
              "11月",
              "12月"
            ]
          },
          "y": {
            "unit": "万辆",
            "range": {
              "min": 0,
              "max": 100
            }
          }
        },
        "series": [
          {
            "name": "销量",
            "unit": "万辆",
            "values": [
              43.1,
              33.4,
              45.5,
              29.9,
              44.7,
              59.6,
              56.7,
              66.6,
              70.8,
              71.4,
              78.6,
              80.0
            ]
          }
        ],
        "figure_id": "f1ae516a50117965",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 1,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Nov-14",
              "Mar-15",
              "Jul-15",
              "Nov-15",
              "Mar-16",
              "Jul-16",
              "Nov-16",
              "Mar-17",
              "Jul-17",
              "Nov-17",
              "Mar-18",
              "Jul-18",
              "Nov-18",
              "Mar-19",
              "Jul-19",
              "Nov-19",
              "Mar-20",
              "Jul-20",
              "Nov-20",
              "Mar-21",
              "Jul-21",
              "Nov-21",
              "Mar-22",
              "Jul-22",
              "Nov-22",
              "Mar-23",
              "Jul-23",
              "Nov-23",
              "Mar-24",
              "Jul-24",
              "Nov-24",
              "Mar-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": "A$ per share",
            "range": {
              "min": 1.5,
              "max": 5.5
            }
          }
        },
        "series": [
          {
            "name": "Value",
            "unit": "A$ per share",
            "values": [
              2.15,
              2.4,
              2.05,
              2.3,
              2.8,
              3.25,
              2.9,
              2.7,
              3.0,
              3.3,
              2.95,
              2.75,
              2.5,
              3.6,
              3.0,
              2.8,
              2.5,
              3.0,
              3.2,
              3.6,
              3.3,
              3.0,
              3.7,
              3.3,
              3.5,
              3.6,
              3.8,
              3.9,
              4.2,
              4.5,
              4.9,
              5.1,
              5.2
            ]
          }
        ],
        "figure_id": "0196daa0ffecfde1",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 1,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Jan-15",
              "Jul-15",
              "Jan-16",
              "Jul-16",
              "Jan-17",
              "Jul-17",
              "Jan-18",
              "Jul-18",
              "Jan-19",
              "Jul-19",
              "Jan-20",
              "Jul-20",
              "Jan-21",
              "Jul-21",
              "Jan-22",
              "Jul-22",
              "Jan-23",
              "Jul-23",
              "Jan-24",
              "Jul-24",
              "Jan-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": "A$ per share",
            "range": {
              "min": 1.5,
              "max": 6.0
            }
          }
        },
        "series": [
          {
            "name": "Upper",
            "unit": "A$ per share",
            "values": [
              2.6,
              3.1,
              3.6,
              3.9,
              3.8,
              3.8,
              3.9,
              3.9,
              3.2,
              2.4,
              3.9,
              3.9,
              3.5,
              3.0,
              2.3,
              2.0,
              3.0,
              3.8,
              4.4,
              4.8,
              5.3,
              5.6
            ]
          },
          {
            "name": "Current",
            "unit": "A$ per share",
            "values": [
              2.4,
              2.9,
              3.3,
              3.6,
              3.5,
              3.5,
              3.6,
              3.6,
              2.9,
              2.2,
              3.6,
              3.6,
              3.2,
              2.7,
              2.1,
              1.8,
              2.7,
              3.5,
              4.1,
              4.5,
              5.0,
              5.3
            ]
          },
          {
            "name": "Mean",
            "unit": "A$ per share",
            "values": [
              2.2,
              2.7,
              3.1,
              3.4,
              3.3,
              3.3,
              3.4,
              3.4,
              2.7,
              2.0,
              3.4,
              3.4,
              3.0,
              2.5,
              1.9,
              1.6,
              2.5,
              3.3,
              3.9,
              4.3,
              4.8,
              5.1
            ]
          },
          {
            "name": "Lower",
            "unit": "A$ per share",
            "values": [
              2.0,
              2.5,
              2.9,
              3.2,
              3.1,
              3.1,
              3.2,
              3.2,
              2.5,
              1.8,
              3.2,
              3.2,
              2.8,
              2.3,
              1.7,
              1.4,
              2.3,
              3.1,
              3.7,
              4.1,
              4.6,
              4.9
            ]
          },
          {
            "name": "Value",
            "unit": "A$ per share",
            "values": [
              2.4,
              2.0,
              2.8,
              3.3,
              2.9,
              3.2,
              3.0,
              3.3,
              2.5,
              3.7,
              2.8,
              3.5,
              2.9,
              3.6,
              2.8,
              3.7,
              3.0,
              3.8,
              3.5,
              4.0,
              3.8,
              4.5
            ]
          }
        ],
        "figure_id": "73a3bf8b8507b76d",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 2,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2024",
              "2025",
              "+12 mo."
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 3,
              "max": 6.5
            }
          }
        },
        "series": [
          {
            "name": "Historical Data",
            "unit": null,
            "values": [
              {
                "x": "2024",
                "y": 3.5
              },
              {
                "x": "2025",
                "y": 5.1
              }
            ]
          },
          {
            "name": "Forecast - Upside",
            "unit": null,
            "values": [
              {
                "x": "2025",
                "y": 5.1
              },
              {
                "x": "+12 mo.",
                "y": 6.48
              }
            ]
          },
          {
            "name": "Forecast - Midpoint",
            "unit": null,
            "values": [
              {
                "x": "2025",
                "y": 5.1
              },
              {
                "x": "+12 mo.",
                "y": 5.4
              }
            ]
          },
          {
            "name": "Forecast - Downside",
            "unit": null,
            "values": [
              {
                "x": "2025",
                "y": 5.1
              },
              {
                "x": "+12 mo.",
                "y": 4.32
              }
            ]
          }
        ],
        "figure_id": "e201614eca96f974",
        "provenance": {
          "page": 2
        }
      },
      {
        "type": "pie",
        "title": null,
        "page": 4,
        "axes": null,
        "series": [
          {
            "name": "Medibank Health",
            "unit": "%",
            "values": [
              15
            ]
          },
          {
            "name": "Health insurance",
            "unit": "%",
            "values": [
              85
            ]
          }
        ],
        "figure_id": "b17b060f087034f1",
        "provenance": {
          "page": 4
        }
      },
      {
        "type": "pie",
        "title": null,
        "page": 5,
        "axes": null,
        "series": [
          {
            "name": "Fixed income",
            "unit": "%",
            "values": [
              62
            ]
          },
          {
            "name": "Cash",
            "unit": "%",
            "values": [
              20
            ]
          },
          {
            "name": "Infrastructure",
            "unit": "%",
            "values": [
              6
            ]
          },
          {
            "name": "Property",
            "unit": "%",
            "values": [
              5
            ]
          },
          {
            "name": "Australian equities",
            "unit": "%",
            "values": [
              3
            ]
          },
          {
            "name": "International equities",
            "unit": "%",
            "values": [
              4
            ]
          }
        ],
        "figure_id": "e8ce329c085114a7",
        "provenance": {
          "page": 5
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 8,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Jan-15",
              "Jul-15",
              "Jan-16",
              "Jul-16",
              "Jan-17",
              "Jul-17",
              "Jan-18",
              "Jul-18",
              "Jan-19",
              "Jul-19",
              "Jan-20",
              "Jul-20",
              "Jan-21",
              "Jul-21",
              "Jan-22",
              "Jul-22",
              "Jan-23",
              "Jul-23",
              "Jan-24",
              "Jul-24",
              "Jan-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": "A$ per share",
            "range": {
              "min": 1.5,
              "max": 6.0
            }
          }
        },
        "series": [
          {
            "name": "Upper",
            "unit": "A$ per share",
            "values": [
              2.6,
              3.0,
              3.5,
              3.9,
              3.8,
              3.8,
              3.8,
              3.8,
              3.7,
              3.8,
              3.9,
              3.9,
              3.9,
              3.9,
              3.9,
              3.9,
              4.4,
              4.4,
              4.4,
              5.0,
              5.5,
              5.8
            ]
          },
          {
            "name": "Mean",
            "unit": "A$ per share",
            "values": [
              2.5,
              2.8,
              3.2,
              3.5,
              3.4,
              3.4,
              3.4,
              3.4,
              3.3,
              3.4,
              3.5,
              3.5,
              3.5,
              3.5,
              3.5,
              3.5,
              4.0,
              4.0,
              4.0,
              4.6,
              5.0,
              5.3
            ]
          },
          {
            "name": "Current",
            "unit": "A$ per share",
            "values": [
              2.3,
              2.6,
              3.0,
              3.3,
              3.2,
              3.2,
              3.2,
              3.2,
              3.1,
              3.2,
              3.3,
              3.3,
              3.3,
              3.3,
              3.3,
              3.3,
              3.8,
              3.8,
              3.8,
              4.4,
              4.8,
              5.1
            ]
          },
          {
            "name": "Lower",
            "unit": "A$ per share",
            "values": [
              2.1,
              2.3,
              2.6,
              2.9,
              2.8,
              2.8,
              2.8,
              2.8,
              2.7,
              2.8,
              2.9,
              2.9,
              2.9,
              2.9,
              2.9,
              2.9,
              3.4,
              3.4,
              3.4,
              4.0,
              4.4,
              4.7
            ]
          },
          {
            "name": "Actual",
            "unit": "A$ per share",
            "values": [
              2.4,
              2.0,
              2.3,
              2.7,
              2.9,
              3.2,
              3.0,
              3.3,
              2.8,
              3.6,
              2.9,
              3.3,
              2.8,
              3.0,
              2.7,
              3.2,
              3.5,
              3.9,
              4.0,
              4.5,
              4.9,
              5.2
            ]
          }
        ],
        "figure_id": "c378685d8d679f99",
        "provenance": {
          "page": 8
        }
      },
      {
        "type": "line",
        "title": "Rating and Price Target History for: Medibank Private Limited (MPL AU) as of 08-27-2025",
        "page": 12,
        "axes": {
          "x": {
            "type": "time",
            "labels": [
              "Oct 22",
              "Jan 23",
              "Apr 23",
              "Jul 23",
              "Oct 23",
              "Jan 24",
              "Apr 24",
              "Jul 24",
              "Oct 24",
              "Jan 25",
              "Apr 25",
              "Jul 25"
            ]
          },
          "y": {
            "unit": "AUD",
            "range": {
              "min": 2.5,
              "max": 5.5
            }
          }
        },
        "series": [
          {
            "name": "Price",
            "unit": "AUD",
            "values": [
              {
                "date": "2022-10-27",
                "value": 3.75
              },
              {
                "date": "2023-01-24",
                "value": 3.7
              },
              {
                "date": "2023-02-23",
                "value": 3.9
              },
              {
                "date": "2023-02-23",
                "value": 3.7
              },
              {
                "date": "2023-05-02",
                "value": 3.7
              },
              {
                "date": "2023-07-17",
                "value": 3.55
              },
              {
                "date": "2023-08-24",
                "value": 4.0
              },
              {
                "date": "2023-12-01",
                "value": 4.0
              },
              {
                "date": "2024-01-11",
                "value": 4.3
              },
              {
                "date": "2024-02-23",
                "value": 4.2
              },
              {
                "date": "2024-04-25",
                "value": 4.3
              },
              {
                "date": "2024-08-02",
                "value": 4.5
              },
              {
                "date": "2024-08-22",
                "value": 4.55
              },
              {
                "date": "2025-01-16",
                "value": 4.4
              },
              {
                "date": "2025-02-27",
                "value": 4.8
              }
            ]
          }
        ],
        "figure_id": "1fb9652bcb164fc9",
        "provenance": {
          "page": 12
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "0fcee9205cb9579e",
        "value": 0.085,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "contribution from Medibank Health and higher investment returns see MPL's underlying NPAT increase 8.5%. In FY26E, MPL expect moderating industry growth and increased resident claiming rates whilst pr",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "62ad32a5979ed5e2",
        "value": 0.013999999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "in** **resident** **and** **non-resident** **policyholders.** MPL saw net resident policy growth of 1.4% on pcp (vs JEF 0.7%) and higher margin, non-resident policy unit growth of 3.1% (vs JEF at 5.8%",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "cc6b626d750ff26a",
        "value": 0.006999999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "and** **non-resident** **policyholders.** MPL saw net resident policy growth of 1.4% on pcp (vs JEF 0.7%) and higher margin, non-resident policy unit growth of 3.1% (vs JEF at 5.8%). Average claims pe",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "9ce5cce28fd002b8",
        "value": 0.031,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "nt policy growth of 1.4% on pcp (vs JEF 0.7%) and higher margin, non-resident policy unit growth of 3.1% (vs JEF at 5.8%). Average claims per policy unit grew 2.2% (vs guidance of 2.4-2.6%, JEF at 2.6",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "593666990defdbef",
        "value": 0.057999999999999996,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "of 1.4% on pcp (vs JEF 0.7%) and higher margin, non-resident policy unit growth of 3.1% (vs JEF at 5.8%). Average claims per policy unit grew 2.2% (vs guidance of 2.4-2.6%, JEF at 2.6%). FY25 underlyi",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "413cb8773f1f4435",
        "value": 0.022000000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "rgin, non-resident policy unit growth of 3.1% (vs JEF at 5.8%). Average claims per policy unit grew 2.2% (vs guidance of 2.4-2.6%, JEF at 2.6%). FY25 underlying NPAT increased 8.5% on pcp to A&#36;619",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "71969a1fa5c2faad",
        "value": -0.026000000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "y unit growth of 3.1% (vs JEF at 5.8%). Average claims per policy unit grew 2.2% (vs guidance of 2.4-2.6%, JEF at 2.6%). FY25 underlying NPAT increased 8.5% on pcp to A&#36;619m (vs FactSet cons A&#36",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "229e3fadf1d51c10",
        "value": 0.026000000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "of 3.1% (vs JEF at 5.8%). Average claims per policy unit grew 2.2% (vs guidance of 2.4-2.6%, JEF at 2.6%). FY25 underlying NPAT increased 8.5% on pcp to A&#36;619m (vs FactSet cons A&#36;607m, JEF at ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "e0da3ba0b24b3648",
        "value": 0.085,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ms per policy unit grew 2.2% (vs guidance of 2.4-2.6%, JEF at 2.6%). FY25 underlying NPAT increased 8.5% on pcp to A&#36;619m (vs FactSet cons A&#36;607m, JEF at A&#36;621m), driven by resilient polic",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "b1b6fb80f9861672",
        "value": -0.028999999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "urance despite moderating system growth. Resident claims per policy unit are expected to grow by 2.6-2.9%. Non-resident gross profit is expected to grow. Low-double-digit organic growth is expected fo",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "98884405d52445cc",
        "value": 0.022000000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "esourcing recovers. ![Figure 0-2](images/0_2.jpg) **MPL** **Underlying** **NPAT** **decreases** **2.2%** **in** **FY26E** **and** **2.4%** **in** **FY27E.** Changes to our FY26E forecasts include, 1)h",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "c161818d8fe6f720",
        "value": 0.024,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "(images/0_2.jpg) **MPL** **Underlying** **NPAT** **decreases** **2.2%** **in** **FY26E** **and** **2.4%** **in** **FY27E.** Changes to our FY26E forecasts include, 1)health insurance policy unit growt",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "4efc9aa20dd3fdf1",
        "value": 0.013999999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "**in** **FY27E.** Changes to our FY26E forecasts include, 1)health insurance policy unit growth of 1.4% (from 1.5%); 2) Net resident claims/policy unit growth of 2.7% (from 2.6%); 3) Health insurance ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "754d3239d52dc70b",
        "value": 0.015,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Y27E.** Changes to our FY26E forecasts include, 1)health insurance policy unit growth of 1.4% (from 1.5%); 2) Net resident claims/policy unit growth of 2.7% (from 2.6%); 3) Health insurance management",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "8fcc1d905fa79e06",
        "value": 0.027000000000000003,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "alth insurance policy unit growth of 1.4% (from 1.5%); 2) Net resident claims/policy unit growth of 2.7% (from 2.6%); 3) Health insurance management expenses of A&#36;687m (from A&#36;677m), and 4) Ne",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "4ea88507a1a7ed80",
        "value": 0.026000000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "nce policy unit growth of 1.4% (from 1.5%); 2) Net resident claims/policy unit growth of 2.7% (from 2.6%); 3) Health insurance management expenses of A&#36;687m (from A&#36;677m), and 4) Net investmen",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "2c4a76faec78be53",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td>PRICE</td><td>AUD5.02*</td></tr><tr><td>PRICE TARGET|% TO PT</td><td>↑AUD5.40(AUD4.80)|+8%</td></tr><tr><td>52W HIGH-LOW</td><td>AUD5.31-AUD3.53</td></tr><tr><td>FLOAT(%)|ADV MM (USD)</td",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "a28f31b21077903a",
        "value": 0.9990000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></tr><tr><td>52W HIGH-LOW</td><td>AUD5.31-AUD3.53</td></tr><tr><td>FLOAT(%)|ADV MM (USD)</td><td>99.9%|25.06</td></tr><tr><td>MARKET CAP</td><td>AUD13.8B|$9.0B</td></tr><tr><td>TICKER</td><td>MPL A",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "461691a4329aca7c",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>JEF vs CONS</td></tr><tr><td></td><td>2026</td><td>2027 2026 2027</td></tr><tr><td>REV</td><td>+1%</td><td>+2% NM +1%</td></tr><tr><td>EPS</td><td>-2%</td><td>-2% -2% +1%</td></tr><tr><td></td><t",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "0f940d09425ad77b",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "CONS</td></tr><tr><td></td><td>2026</td><td>2027 2026 2027</td></tr><tr><td>REV</td><td>+1%</td><td>+2% NM +1%</td></tr><tr><td>EPS</td><td>-2%</td><td>-2% -2% +1%</td></tr><tr><td></td><td></td><td><",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "1ab0f5a0e93382cf",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></tr><tr><td></td><td>2026</td><td>2027 2026 2027</td></tr><tr><td>REV</td><td>+1%</td><td>+2% NM +1%</td></tr><tr><td>EPS</td><td>-2%</td><td>-2% -2% +1%</td></tr><tr><td></td><td></td><td></td></t",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "c758693ac0f1e4d8",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>2027 2026 2027</td></tr><tr><td>REV</td><td>+1%</td><td>+2% NM +1%</td></tr><tr><td>EPS</td><td>-2%</td><td>-2% -2% +1%</td></tr><tr><td></td><td></td><td></td></tr><tr><td>2026(AUD)</td><td>1Half",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "f882eebb8276c833",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6 2027</td></tr><tr><td>REV</td><td>+1%</td><td>+2% NM +1%</td></tr><tr><td>EPS</td><td>-2%</td><td>-2% -2% +1%</td></tr><tr><td></td><td></td><td></td></tr><tr><td>2026(AUD)</td><td>1Half</td><td>2Ha",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "5393927ce799103a",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "27</td></tr><tr><td>REV</td><td>+1%</td><td>+2% NM +1%</td></tr><tr><td>EPS</td><td>-2%</td><td>-2% -2% +1%</td></tr><tr><td></td><td></td><td></td></tr><tr><td>2026(AUD)</td><td>1Half</td><td>2Half F",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "3af0bbd4abb25f31",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></tr><tr><td>REV</td><td>+1%</td><td>+2% NM +1%</td></tr><tr><td>EPS</td><td>-2%</td><td>-2% -2% +1%</td></tr><tr><td></td><td></td><td></td></tr><tr><td>2026(AUD)</td><td>1Half</td><td>2Half FY</t",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "4f0e6505a053fd8a",
        "value": 9000000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</tr><tr><td>FLOAT(%)|ADV MM (USD)</td><td>99.9%|25.06</td></tr><tr><td>MARKET CAP</td><td>AUD13.8B|$9.0B</td></tr><tr><td>TICKER</td><td>MPL AU</td></tr></table> *Prior trading day's closing price un",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "fa98480de29bca4f",
        "value": 0.27,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ere We Differ MPL provides a defensive investment opportunity with a market- leading position of c.27% share, positive upside to rising interest rates, strong balance sheet with no debt, and the bulk ",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "9bfba3bb63b4c476",
        "value": 1.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "570</td><td>619</td><td>636</td><td>689</td><td>737</td></tr><tr><td>JEF Adj NPAT/consensus</td><td>100%</td><td>100%</td><td>99%</td><td>102%</td><td>107%</td></tr><tr><td>Normalised EPS (A&amp;amp;c",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "9382ef90f7f26c2c",
        "value": 1.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "19</td><td>636</td><td>689</td><td>737</td></tr><tr><td>JEF Adj NPAT/consensus</td><td>100%</td><td>100%</td><td>99%</td><td>102%</td><td>107%</td></tr><tr><td>Normalised EPS (A&amp;amp;c)</td><td>17.",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "7570692dceb4c665",
        "value": 0.99,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6</td><td>689</td><td>737</td></tr><tr><td>JEF Adj NPAT/consensus</td><td>100%</td><td>100%</td><td>99%</td><td>102%</td><td>107%</td></tr><tr><td>Normalised EPS (A&amp;amp;c)</td><td>17.9</td><td>18.",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "93f79f295d5f23e0",
        "value": 1.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "9</td><td>737</td></tr><tr><td>JEF Adj NPAT/consensus</td><td>100%</td><td>100%</td><td>99%</td><td>102%</td><td>107%</td></tr><tr><td>Normalised EPS (A&amp;amp;c)</td><td>17.9</td><td>18.2</td><td>23",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "037d6b919ed9738c",
        "value": 1.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td></tr><tr><td>JEF Adj NPAT/consensus</td><td>100%</td><td>100%</td><td>99%</td><td>102%</td><td>107%</td></tr><tr><td>Normalised EPS (A&amp;amp;c)</td><td>17.9</td><td>18.2</td><td>23.1</td><td>25",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "5e9da3583bff216d",
        "value": 619.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "dance of \\(2.4 - 2.6\\%\\) , JEF at \\(2.6\\%\\) ). FY25 underlying NPAT increased \\(8.5\\%\\) on pcp to A\\$619m (vs FactSet cons A\\$607m, JEF at A\\$621m), driven by resilient policy growth, better- than- ex",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "8b45bf3f79c84833",
        "value": 607.0,
        "unit": "$",
        "metric_type": "currency",
        "context": ", JEF at \\(2.6\\%\\) ). FY25 underlying NPAT increased \\(8.5\\%\\) on pcp to A\\$619m (vs FactSet cons A\\$607m, JEF at A\\$621m), driven by resilient policy growth, better- than- expected claims inflation a",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "fa46810bb2398ff8",
        "value": 621.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "\\) ). FY25 underlying NPAT increased \\(8.5\\%\\) on pcp to A\\$619m (vs FactSet cons A\\$607m, JEF at A\\$621m), driven by resilient policy growth, better- than- expected claims inflation and effective mar",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "16940c958b8312a9",
        "value": 35.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "to grow. Low- double- digit organic growth is expected for Medibank Health. Cybercrime costs of cA\\$35m are forecast. Differences compared to our forecasts include: 1) Higher- than- expected Gross Pro",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "abfbe2eb8b7c0cd9",
        "value": 687.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "ims/policy unit growth of \\(2.7\\%\\) (from \\(2.6\\%\\) ); 3) Health insurance management expenses of A\\$687m (from A\\$677m), and 4) Net investment income of A\\$178m (from A\\$155m). Consequently, we reduc",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "69762a5a5e789498",
        "value": 677.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "t growth of \\(2.7\\%\\) (from \\(2.6\\%\\) ); 3) Health insurance management expenses of A\\$687m (from A\\$677m), and 4) Net investment income of A\\$178m (from A\\$155m). Consequently, we reduce underlying N",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "cd8f80bb20a98274",
        "value": 178.0,
        "unit": "$",
        "metric_type": "currency",
        "context": ") Health insurance management expenses of A\\$687m (from A\\$677m), and 4) Net investment income of A\\$178m (from A\\$155m). Consequently, we reduce underlying NPAT by \\(2.2\\%\\) in FY26E and \\(2.4\\%\\) in",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "2a9d7fd0b9d87176",
        "value": 155.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "ance management expenses of A\\$687m (from A\\$677m), and 4) Net investment income of A\\$178m (from A\\$155m). Consequently, we reduce underlying NPAT by \\(2.2\\%\\) in FY26E and \\(2.4\\%\\) in FY27E. Figure",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "4c65da648742e586",
        "value": 0.85,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ter>Figure 5 - Segment operating profit FY26E </center> Source: JEF estimates - Health Insurance (85% of FY26E Operating Profit): FY25 premium revenue increased by \\(4.1\\%\\) to A\\$8.2bn (vs. JEF at A\\",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "fbee1ae679582a26",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ill further differentiate its brands by investing in new products and services. - Medibank Health (15% of FY26E Operating Profit): Revenue increased \\(34.7\\%\\) to A\\$485m with FY25 gross profit of A\\$",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "c63b38ebf40c8e4a",
        "value": 10.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "FY25.- Net resident claims per policy unit growth of \\(2.6\\% - 2.9\\%\\) .- Productivity savings of A\\$10m.- Cybercrime costs expected to be cA\\$35m.- Low-double-digit organic operating profit growth is",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "237106966f0d4f17",
        "value": 35.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "growth of \\(2.6\\% - 2.9\\%\\) .- Productivity savings of A\\$10m.- Cybercrime costs expected to be cA\\$35m.- Low-double-digit organic operating profit growth is expected for Medibank Health. ## Key Insig",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "92f6dc6ca27387d9",
        "value": 8.6,
        "unit": "$",
        "metric_type": "currency",
        "context": "h. ## Key Insights - MPL Group revenue from external customers - Increased \\(5.2\\%\\) on pcp to A\\$8.6bn (from A \\(8.2bn in FY24), with solid growth in resident policyholders. ![Figure 3-0](images/3_0.",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "03a1c75bd16b92f0",
        "value": 8.2,
        "unit": "$",
        "metric_type": "currency",
        "context": "Health Insurance (85% of FY26E Operating Profit): FY25 premium revenue increased by \\(4.1\\%\\) to A\\$8.2bn (vs. JEF at A\\$8.2bn). FY25 Gross Profit was A\\$1,396m (vs. JEF at A\\$1,376m), benefiting from",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "b30de74ffec584fa",
        "value": 8.2,
        "unit": "$",
        "metric_type": "currency",
        "context": "% of FY26E Operating Profit): FY25 premium revenue increased by \\(4.1\\%\\) to A\\$8.2bn (vs. JEF at A\\$8.2bn). FY25 Gross Profit was A\\$1,396m (vs. JEF at A\\$1,376m), benefiting from MPL's treatment of ",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "b2d4bb60a97d3b97",
        "value": 1396.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "5 premium revenue increased by \\(4.1\\%\\) to A\\$8.2bn (vs. JEF at A\\$8.2bn). FY25 Gross Profit was A\\$1,396m (vs. JEF at A\\$1,376m), benefiting from MPL's treatment of COVID-19 claims trends. Net resid",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "b6918bd57ce4195c",
        "value": 1376.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "eased by \\(4.1\\%\\) to A\\$8.2bn (vs. JEF at A\\$8.2bn). FY25 Gross Profit was A\\$1,396m (vs. JEF at A\\$1,376m), benefiting from MPL's treatment of COVID-19 claims trends. Net resident policyholders incr",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "ef79918d9fef1f4e",
        "value": 485.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "and services. - Medibank Health (15% of FY26E Operating Profit): Revenue increased \\(34.7\\%\\) to A\\$485m with FY25 gross profit of A\\$277m. Operating margin decreased 40bps to \\(17.4\\%\\) . In FY25, Me",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "d9529ec97f2b70d6",
        "value": 277.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "15% of FY26E Operating Profit): Revenue increased \\(34.7\\%\\) to A\\$485m with FY25 gross profit of A\\$277m. Operating margin decreased 40bps to \\(17.4\\%\\) . In FY25, Medibank Health generated \\(23.0\\%\\",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "530a20c534ace4e2",
        "value": 3.64,
        "unit": "$",
        "metric_type": "currency",
        "context": "\\) ). - Investment income: At \\(30^{\\text{th}}\\) June 2025, MPL held investment assets totalling A\\$3.64bn (with Total Assets on Balance Sheet of A\\$4.70bn, up \\(0.3\\%\\) on pcp). In FY25, MPL's invest",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "c5a5822944116478",
        "value": 4.7,
        "unit": "$",
        "metric_type": "currency",
        "context": "June 2025, MPL held investment assets totalling A\\$3.64bn (with Total Assets on Balance Sheet of A\\$4.70bn, up \\(0.3\\%\\) on pcp). In FY25, MPL's investment assets generated an underlying return of \\(5",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "18649b0bef6d6566",
        "value": 9.1,
        "unit": "$",
        "metric_type": "currency",
        "context": "o forecasts Changes to our MPL forecasts include: Revenue: In FY26E, we assume Total Revenue of A\\$9.1bn (from A\\$9.0bn).- Health insurance net claims expense: We have assumed health insurance net cla",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "001954fe666290b0",
        "value": 9.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "anges to our MPL forecasts include: Revenue: In FY26E, we assume Total Revenue of A\\$9.1bn (from A\\$9.0bn).- Health insurance net claims expense: We have assumed health insurance net claims expenses w",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "655dbbdd9ee1c746",
        "value": 7.4,
        "unit": "$",
        "metric_type": "currency",
        "context": "Health insurance net claims expense: We have assumed health insurance net claims expenses will be A\\$7.4bn in FY26E (from A\\$7.3bn).- Management expense: We assume Total management expenses of A\\$908m",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "103735afa37cc17c",
        "value": 7.3,
        "unit": "$",
        "metric_type": "currency",
        "context": "ims expense: We have assumed health insurance net claims expenses will be A\\$7.4bn in FY26E (from A\\$7.3bn).- Management expense: We assume Total management expenses of A\\$908m in FY26E (from A\\$894m)",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "dcb96bf0728ea5dc",
        "value": 908.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "be A\\$7.4bn in FY26E (from A\\$7.3bn).- Management expense: We assume Total management expenses of A\\$908m in FY26E (from A\\$894m).- Investment income: In FY26E, we assume a weighted average investment",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "a24ca89e573fa537",
        "value": 894.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "rom A\\$7.3bn).- Management expense: We assume Total management expenses of A\\$908m in FY26E (from A\\$894m).- Investment income: In FY26E, we assume a weighted average investment return of \\(5.2\\%\\) .-",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "b7a7ff62421a13c0",
        "value": 0.19,
        "unit": "$",
        "metric_type": "currency",
        "context": "Payout ratio: Our assumed dividend payout ratio is \\(80\\%\\) , implying a FY26E total dividend of A\\$0.19.<｜end▁of▁sentence｜>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "e2d17820efe19f3d",
        "value": 5.4,
        "unit": "$",
        "metric_type": "currency",
        "context": "omparable multiples, which have increased. Consequently, we increase our price target for MPL to A\\\\$5.40. We use an equally weighted blended valuation of DCF, P/E, and P/BV per share multiples. Based",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "eb5d08ac9c154f10",
        "value": 4.07,
        "unit": "$",
        "metric_type": "currency",
        "context": "ate, \\(8.4\\%\\) COE and \\(8.4\\%\\) WACC, the DCF component of our valuation is A \\(3.65\\) (up from A\\\\$4.07), normalised P/E multiple of 29.6x FY2 EPS (from 23.5x) and P/BV multiple of 5.0x FY2 P/BV (fr",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "03e7b99524061e4f",
        "value": 15.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "re) <table><tr><td>Metric</td><td>Weight (%)</td><td>Valuation (A$ps)</td><td>Weighted valuation (A$15:1)</td></tr><tr><td>DCF Valuation (12 month forward)</td><td>33.3</td><td>3.65</td><td>1.22</td><",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "da8c79e1185e5734",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>9,077</td><td>9,611</td><td>10,173</td><td>DCF valuation</td><td>Upside/(Downside) to TP</td><td>8%</td><td></td></tr><tr><td>Health insurance net claims expense</td><td>(6,596)</td><td>(6,815)</td",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "2e3f499a0ca4c297",
        "value": 0.071,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "assets</td><td>467</td><td>500</td><td>524</td><td>552</td><td>580</td><td>Health insurance</td><td>7.1%</td><td>-26.3%</td><td>48.9%</td></tr><tr><td>Other LT assets</td><td>207</td><td>195</td><td>5",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "94d589efc5e5a172",
        "value": -0.263,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>467</td><td>500</td><td>524</td><td>552</td><td>580</td><td>Health insurance</td><td>7.1%</td><td>-26.3%</td><td>48.9%</td></tr><tr><td>Other LT assets</td><td>207</td><td>195</td><td>51</td><td>54<",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "642e9c07e9bec266",
        "value": 0.489,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "00</td><td>524</td><td>552</td><td>580</td><td>Health insurance</td><td>7.1%</td><td>-26.3%</td><td>48.9%</td></tr><tr><td>Other LT assets</td><td>207</td><td>195</td><td>51</td><td>54</td><td>57</td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "b1f5df5d5839a4c4",
        "value": 0.312,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "LT assets</td><td>207</td><td>195</td><td>51</td><td>54</td><td>57</td><td>Medibank Health</td><td>31.2%</td><td>15.0%</td><td>15.0%</td></tr><tr><td>Total assets</td><td>4,685</td><td>4,700</td><td>4",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "f7c947535b24cd91",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>207</td><td>195</td><td>51</td><td>54</td><td>57</td><td>Medibank Health</td><td>31.2%</td><td>15.0%</td><td>15.0%</td></tr><tr><td>Total assets</td><td>4,685</td><td>4,700</td><td>4,979</td><td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "2264058e1eac828a",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>195</td><td>51</td><td>54</td><td>57</td><td>Medibank Health</td><td>31.2%</td><td>15.0%</td><td>15.0%</td></tr><tr><td>Total assets</td><td>4,685</td><td>4,700</td><td>4,979</td><td>5,288</td><td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "a84e7260b904e80c",
        "value": 0.141,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "10</td><td>2,700</td><td>2,898</td><td>(Health insurance (Net cash capital)/[Next 12m prem)</td><td>14.1%</td><td>13.9%</td><td>13.8%</td></tr><tr><td>Total equity &amp; liabilities</td><td>4,685</td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "15e8ac18ee315e55",
        "value": 0.139,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "00</td><td>2,898</td><td>(Health insurance (Net cash capital)/[Next 12m prem)</td><td>14.1%</td><td>13.9%</td><td>13.8%</td></tr><tr><td>Total equity &amp; liabilities</td><td>4,685</td><td>4,700</td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "0017df7c87e663e9",
        "value": 0.138,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "98</td><td>(Health insurance (Net cash capital)/[Next 12m prem)</td><td>14.1%</td><td>13.9%</td><td>13.8%</td></tr><tr><td>Total equity &amp; liabilities</td><td>4,685</td><td>4,700</td><td>4,979</td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "bd710054f1825b29",
        "value": 0.6069,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>Count</td><td>Percent</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2112</td><td>60.69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "19cddc8ed6f225d4",
        "value": 0.17379999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2112</td><td>60.69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "d7daaa53ab24fc9d",
        "value": 0.0554,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ent</td></tr><tr><td>BUY</td><td>2112</td><td>60.69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "6a137bdd6288ea81",
        "value": 0.348,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157<",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "91d86855a7d8f1b3",
        "value": 0.0867,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "3173741a92723c06",
        "value": 0.0182,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td>",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "c7c5c1c4852f8f0f",
        "value": 0.0451,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td><td>1.91%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "17611ea6a815b99b",
        "value": 0.0191,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td><td>1.91%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "1b40fca233931134",
        "value": 0.0191,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td><td>1.91%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 11
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 8,
      "tables_count": 0,
      "numerical_data_count": 82,
      "passages_count": 122,
      "entities_count": 20
    }
  }
}